Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
about
Wegener's granulomatosis: current and upcoming therapiesAnti-TNF-alpha therapy and systemic vasculitis.Advances in the use of biologic agents for the treatment of systemic vasculitisA strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.Perspectives for TNF-alpha-targeting therapies.Upper respiratory tract symptoms, renal involvement and vasculitis: a case report and review of wegener granulomatosis.Immunotherapy for autoimmune and inflammatory renal diseases.Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis.Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Biologic therapies: what and when?Etanercept: a clinical review of current and emerging indications.The utility of tumour necrosis factor blockade in orphan diseases.A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Biological therapies: new treatment options for ANCA-associated vasculitis?ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.Update on the use of biologics in primary systemic vasculitides.New indications for biological therapies.The role of biologics in treatment of ANCA-associated vasculitis.Wegener's granulomatosis with pulmonary fungal infection: a case report and brief review.TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis.Management of Small Vessel Vasculitides.[Treatment strategies for ANCA-associated vasculitides].Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases.Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?Etanercept treatment-related c-ANCA-associated large vessel vasculitis.
P2860
Q24804964-729E9959-4E5A-4004-9703-CC69D8370E97Q27687590-86DB594D-52AF-4435-B523-D84E85B56CB9Q34065598-E1C5FD46-2398-474E-9235-943463749072Q34587431-93DDCB33-F53F-49C8-B1EF-1CC2198022E1Q34731078-94A6ACB3-DFDE-47FC-97BF-B44020585F16Q35015340-0DDAD316-870F-462D-ABCF-8B0AE8D783E6Q35144046-ABEE2892-E356-4AC1-8B04-180385D94FA0Q35216972-4F08B72B-6882-487F-B094-9462E3C24729Q35579503-7EABEE75-116E-4235-A33A-2886403E4E3AQ35579517-CFE9A257-7950-4D4D-B139-735C5A5CF95CQ35770607-02DB7CC3-04FE-4B70-8D36-71017720499CQ35779227-FD3EA18D-ABE6-469A-BCEA-95294370AB98Q35915996-87BF9F69-56E9-4629-A74F-E3484203B570Q36194538-0603EF95-87EB-4286-9CB7-AC1952886042Q36684589-88893C87-5AA9-456A-818E-D59B51361CB6Q36764935-91848258-E667-4D48-A11F-FE44519E4E79Q36802625-DE93A046-0AAE-4E26-8F4C-AF9330E279F8Q37754811-DDCFAFDC-7C01-49F1-BD8E-970A6CC4AF2FQ37947157-DCD4DF45-B7E8-40C3-9363-58F11AA8736AQ37950904-56A8E53C-C1D2-4DAF-8E82-EBC596B1A915Q37994863-694B5B08-628C-4998-A50C-0C2413D8C964Q38041477-6F668B84-0EA7-45C9-96B3-C886574F8782Q38818682-48D7573C-DB9E-4944-ABD9-B777D4D5782DQ41192540-FF181DD3-A74D-45D1-AD50-D15616937C6CQ42948710-76BC5426-62E6-4188-A402-D334C21C01AAQ44641551-1DC7B36D-9304-4C83-8299-5F2299069385Q51066095-8874C959-88D4-4E99-9530-5F211F1E5FA2Q52987447-7BDD7637-129D-4B10-95DF-BCECA9443354
P2860
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Etanercept combined with conve ...... abel trial to evaluate safety.
@en
Etanercept combined with conve ...... abel trial to evaluate safety.
@nl
type
label
Etanercept combined with conve ...... abel trial to evaluate safety.
@en
Etanercept combined with conve ...... abel trial to evaluate safety.
@nl
prefLabel
Etanercept combined with conve ...... abel trial to evaluate safety.
@en
Etanercept combined with conve ...... abel trial to evaluate safety.
@nl
P2093
P1476
Etanercept combined with conve ...... abel trial to evaluate safety.
@en
P2093
P2860
P304
P356
10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F
P577
2001-05-01T00:00:00Z